The Cardiolinc Annual Meeting 2018 was held in Munich during the European Society of Cardiology Congress on August 28, 2018.
We are proud to announce the launch of Cardiolinc™ as a non-profit organization (NPO). The Cardiolinc network mission is understand the role of regulatory RNAs in cardiovascular disease and engage in collaborative research to drive the development and growth of precision medicine.
The recently approved COST Action CARDIOPROTECTION will address the challenge to translate new cardioprotective therapies for heart failure discovered in the laboratory setting into the clinical setting.
The 13th call for proposals of the Innovative Medicines Initiatives 2 (IMI2) will open with a topic on “Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches”.